Mustang Bio, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Mustang Bio, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 6.2 times its market value (net cash). Higher than almost all Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 3,580% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 94% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 3/3Sales grew in 0 of the last 3 years; profit grew in 3 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
6.2× cashCash, after subtracting all debt, is 6.2 times its market value (net cash).
Higher than almost all Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Mustang Bio, Inc. made a loss over the last year. Mustang Bio, Inc. owes $0.52 for every $1 it owns. Mustang Bio, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossMustang Bio, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.37The share price is 0.37 times Mustang Bio, Inc.'s book value per share, lower than 94% of Healthcare companies in United States.
Market cap
$3 MThe total market value of all of Mustang Bio, Inc.'s shares at today's price (share price × number of shares), smaller than 96% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$8 MWhat Mustang Bio, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.00Net worth divided by the number of shares. The share price of $0.37 is 0.4 times this, which is the P/B above.
Return on equity (ROE)
-58.1%Mustang Bio, Inc. lost 58.1% of its shareholders' money over the last year, lower than 55% of Healthcare companies in United States.
Owes vs Owns
0.52×Mustang Bio, Inc. owes $0.52 for every $1 it owns (moderate), higher than 57% of Healthcare companies in United States.
Dividend yield
NoneMustang Bio, Inc. does not currently pay a dividend.
Profit growth
LossMustang Bio, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashMustang Bio, Inc. held $17 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Mustang Bio, Inc.: $3 M ÷ $8 M (30 Jun 2026) = 0.4.
What is Mustang Bio, Inc.'s return on equity?
Mustang Bio, Inc. lost 58.1% of its shareholders' money over the last year, lower than 55% of Healthcare companies in United States.
How much does Mustang Bio, Inc. owe compared with what it owns?
Mustang Bio, Inc. owes $0.52 for every $1 it owns (moderate), higher than 57% of Healthcare companies in United States.
Does Mustang Bio, Inc. pay a dividend?
No. Mustang Bio, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.